Please login to the form below

Not currently logged in
Email:
Password:

Avodart may help prevent prostate cancer

Findings presented at the American Urological Association's annual meeting show that men at risk of prostate cancer were less likely to develop the disease if treated with GSK's Avodart

Findings presented at the American Urological Association's annual meeting, being held in Chicago, show that men at risk of prostate cancer were less likely to develop the disease if treated with GSK's Avodart (dutasteride).

The Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial studied 8,121 men, aged between 50 and 75 years, with prostate specific antigen (PSA) levels between 2.5 and 10ng/ml (for those aged 50–60 years) and between 3.0 and 10.0 ng/ml (for those over 60 years).

Those taking a daily dose of 0.5 mg of Avodart reduced their risk of biopsy-detectable prostate cancer, over four years, by 23 per cent compared with those taking placebo. A total of 1,516 cancers were observed – 659 among those taking Avodart and 857 in the placebo group.

Avodart inhibits 5-alpha reductase enzymes – type 1 and type 2 –which convert testosterone to dihydrotestosterone (DHT) – a hormone with a key role in prostate growth.

GSK has said that a paper including further analysis of the results of the trial will be submitted for publication this year.

28th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics